Want to see MTNB full AI Analyst Report?
Top Page
Matinas BioPharma
(NYSE MKT:MTNB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.32
▼(-50.92% Downside)
Action:Reiterated
Date:07/28/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and sharply reduced equity) and a bearish technical setup (price below all major moving averages). Corporate events add some offsetting potential via the pending merger and asset sale, but the listing-compliance issue and financing dependency remain meaningful risks, while valuation metrics provide limited support due to negative earnings and no dividend.
Positive Factors
Monetization of nanotech assets via sale to Azurity
Selling the nanotechnologies unit generates immediate non-dilutive cash and a structured milestone/royalty stream that can materially extend runway. This structural monetization reduces near-term financing pressure and converts a high-cost R&D asset into contingent, multi-year cash flows.
Negative Factors
No revenue and persistent net losses
With zero reported revenue and recurring negative net income, the firm's business model currently lacks operating cash generation. Over the medium term this forces reliance on external financing or asset monetizations and leaves limited visibility into a sustainable path to profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Monetization of nanotech assets via sale to Azurity
Selling the nanotechnologies unit generates immediate non-dilutive cash and a structured milestone/royalty stream that can materially extend runway. This structural monetization reduces near-term financing pressure and converts a high-cost R&D asset into contingent, multi-year cash flows.
Read all positive factors
Matinas BioPharma (MTNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.02M
Dividend YieldN/A
Average Volume (3M)52.28K
Price to Earnings (P/E)―
Beta (1Y)2.01
Revenue GrowthN/A
EPS Growth49.11%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,692,796
10 Day Avg. Volume45,057
30 Day Avg. Volume52,280
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Matinas BioPharma Business Overview & Revenue Model
Company Description
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology ...
How the Company Makes Money
null...
Matinas BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.10M | 3.19M | 33.00K |
| Gross Profit | -227.00K | -456.00K | -972.00K | 155.00K | -13.49M | -14.55M |
| EBITDA | -9.72M | -9.89M | -19.19M | -22.00M | -20.64M | -23.00M |
| Net Income | -11.23M | -10.35M | -24.25M | -22.94M | -21.00M | -23.28M |
Balance Sheet | ||||||
| Total Assets | 5.87M | 7.21M | 12.64M | 25.10M | 78.87M | 61.33M |
| Cash, Cash Equivalents and Short-Term Investments | 2.45M | 4.00M | 7.28M | 13.76M | 28.81M | 49.62M |
| Total Debt | 1.19M | 1.35M | 2.89M | 3.56M | 4.12M | 4.70M |
| Total Liabilities | 2.85M | 2.38M | 5.05M | 5.86M | 42.23M | 8.83M |
| Stockholders Equity | 3.02M | 4.83M | 7.59M | 19.25M | 36.64M | 52.49M |
Cash Flow | ||||||
| Free Cash Flow | -6.61M | -7.01M | -15.88M | -15.50M | -20.05M | -15.48M |
| Operating Cash Flow | -6.61M | -7.01M | -15.88M | -15.28M | -19.16M | -15.22M |
| Investing Cash Flow | 335.00K | 335.00K | 9.21M | 13.24M | 4.88M | 16.77M |
| Financing Cash Flow | 1.74M | 3.39M | 9.17M | -7.00K | 79.00K | 6.96M |
Matinas BioPharma Technical Analysis
Negative
0.65
Price Trends
0.59
Negative
0.59
Negative
0.73
Negative
Market Momentum
-0.11
Positive
25.11
Positive
3.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.65 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.59, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 25.11 is Positive, neither overbought nor oversold. The STOCH value of 3.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.
Matinas BioPharma Risk Analysis
Matinas BioPharma disclosed 56 risk factors in its most recent earnings report. Matinas BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Matinas BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $7.31M | -0.34 | -162.83% | ― | ― | 75.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $7.68M | -0.35 | -59.54% | ― | -90.40% | 34.76% | |
44 Neutral | $5.11M | -0.06 | -102.39% | ― | 356.16% | 62.82% | |
42 Neutral | $4.02M | -0.14 | -204.27% | ― | ― | 49.11% | |
42 Neutral | $5.49M | -0.14 | -153.80% | ― | ― | 97.61% |
* Healthcare Sector Average
MTNB
Matinas BioPharma
0.29
-0.67
-69.48%
NCNA
Nucana
1.32
-7.82
-85.56%
ADIL
Adial Pharmaceuticals
3.34
-7.05
-67.84%
SILO
Silo Pharma
4.19
-7.44
-63.99%
APRE
Aprea Therapeutics
0.62
-1.08
-63.53%
HCWB
HCW Biologics
3.20
-21.97
-87.29%
Matinas BioPharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Matinas BioPharma Ends At-The-Market Sales Agreement
Neutral
Jul 24, 2026
Matinas BioPharma Holdings, Inc., a biopharmaceutical company that raises capital through public equity offerings, had previously established an at-the-market sales program in July 2020 with BTIG, LLC to sell up to $50 million of its common stock....
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Matinas BioPharma to Merge with GH Power International
Positive
Jul 13, 2026
On July 10, 2026, Matinas BioPharma signed a business combination agreement with Ontario‑based GH Power under which a new parent company, expected to be named GH Power International, will become the NYSE‑listed owner of both firms, cre...
Delistings and Listing ChangesRegulatory Filings and Compliance
Matinas BioPharma Granted NYSE American Compliance Extension
Negative
Jun 26, 2026
On June 24, 2026, Matinas BioPharma received a notice from NYSE American that it was not in compliance with listing standards requiring minimum stockholders’ equity of $4 million, after previously being notified in April 2026 of non-complian...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.